Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8233690 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 8 Pages |
Abstract
Docetaxel is an active agent used in both concurrent and sequential chemoradiotherapy regimens. Mucositis was the major acute toxicity, but this was well tolerated in most subjects. Anemia was the most significant prognostic factor determining survival. Further studies are warranted to investigate the optimal protocol for integrating docetaxel into first-line chemoradiotherapy regimens, as well as the potential additive impact of NAC.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Junichi M.D., Naoyuki M.D., Ph.D., Atsuya M.D., Ph.D., Toshio M.D., Toshiki M.D., Ph.D., Akihiro M.D., Ph.D., Etsuo M.D., Ph.D., Osamu M.D., Masato M.D., Ph.D., Atsushi M.D., Ph.D.,